In breast cancer, however, the partial functional loss of TFEB by the interaction of signal transducer and activator of transcription 3 (STAT3) enhances lysosomal-mediated cell death, thus serving as an anticancer action (Li et al., 2018b). Here, STAT3 is linked to breast cancer.